Adult T-cell leukemia future or investigational therapies

Revision as of 18:42, 25 November 2018 by Aida.J (talk | contribs)
Jump to navigation Jump to search

Adult T-cell leukemia Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adult T-cell leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray Findings

Echocardiography and Ultrasound

CT scan

MRI Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Adult T-cell leukemia future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Adult T-cell leukemia future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adult T-cell leukemia future or investigational therapies

CDC on Adult T-cell leukemia future or investigational therapies

Adult T-cell leukemia future or investigational therapies in the news

Blogs on Adult T-cell leukemia future or investigational therapies

Directions to Hospitals Treating Adult T-cell leukemia

Risk calculators and risk factors for Adult T-cell leukemia future or investigational therapies

Molecular targeting therapy like targeting therapy against NOTCH1/FBXW7 mutations, JAK-STAT signaling pathway and inhibition of the PI3K-signaling pathway are the future investigation therapy for adult t-cell leukemia.[1][2]

  1. Degryse S, de Bock CE, Cox L, Demeyer S, Gielen O, Mentens N, Jacobs K, Geerdens E, Gianfelici V, Hulselmans G, Fiers M, Aerts S, Meijerink JP, Tousseyn T, Cools J (November 2014). "JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model". Blood. 124 (20): 3092–100. doi:10.1182/blood-2014-04-566687. PMID 25193870.
  2. Subramaniam PS, Whye DW, Efimenko E, Chen J, Tosello V, De Keersmaecker K, Kashishian A, Thompson MA, Castillo M, Cordon-Cardo C, Davé UP, Ferrando A, Lannutti BJ, Diacovo TG (April 2012). "Targeting nonclassical oncogenes for therapy in T-ALL". Cancer Cell. 21 (4): 459–72. doi:10.1016/j.ccr.2012.02.029. PMID 22516257.

Template:WH Template:WS